We are analyzing https://link.springer.com/article/10.1007/s00262-016-1923-5.

Title:
Immunological effects of a novel RNA-based adjuvant in liver cancer patients | Cancer Immunology, Immunotherapy
Description:
Evaluation of biological effects of adjuvants on immune cells has been assessed in a limited number of studies. Moreover, no data are available on samples derived from cancer patients who may have a severe immune impairment. The effects of a novel RNA-based adjuvant (RNAdjuvant® developed by CureVac) were assessed in an ex vivo setting on PBMCs obtained from 8 healthy volunteers and 17 HCC patients, using a multiparametric approach to analyze network dynamics of early immune responses. Evaluation of CD80, CD86 and HLA-DR expression, cytokine production as well as gene expression was performed. Moreover, the downstream effect on CD4+ T cell phenotyping was evaluated. Treatment with RNAdjuvant® showed comparable effects on PBMCs of both HCC and healthy subjects. In particular, CD80, CD86 and HLA-DR expression was found up-regulated in circulating dendritic cells, which promoted a CD4+ T cell differentiation toward an effector phenotype. A mixed Th1/Th2 cytokine pattern was induced, although a more predominant production of TNFα and IFNγ was observed in HCC patients versus healthy controls. The cytokine profile was further confirmed by gene transcriptional analysis, which showed up-regulation of several genes involved in innate and adaptive immune-related pathways. The present study is the first demonstration that HCC patients and healthy subjects are equally responsive to an adjuvant. This may suggest that the same vaccine formulation including the RNAdjuvant® might have similar potency in healthy subjects and cancer patients.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Health & Fitness
Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 8,170,236 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We don’t know how the website earns money.

The purpose of some websites isn't monetary gain; they're meant to inform, educate, or foster collaboration. Everyone has unique reasons for building websites. This could be an example. Link.springer.com could be getting rich in stealth mode, or the way it's monetizing isn't detectable.

Keywords {🔍}

article, pubmed, google, scholar, buonaguro, cancer, cas, central, vaccine, patients, tornesello, vaccines, immune, cell, petrizzo, immunotherapy, maria, tagliamonte, cells, subjects, human, effects, adjuvant, adjuvants, pbmcs, healthy, access, receptors, privacy, cookies, content, data, circelli, hcc, dendritic, effector, innate, hepatocellular, virus, memory, author, analysis, publish, research, search, rnabased, heidenreich, luigi, rnadjuvant, expression,

Topics {✒️}

human papillomavirus-16/18-as04-adjuvanted vaccine month download article/chapter favorable safety profile maria lina tornesello hepatocellular carcinoma—hepavac” adaptive immune-related pathways peptide-based anticancer vaccines liver cancer patients hcv-related lymphoproliferative disorders post-licensure safety surveillance cytokine profile hepatocellular carcinoma article cancer immunology author information authors luigi buonaguro cancer vaccine development rna-based adjuvant vivo t-cell responses human immunodeficiency virus author correspondence hiv-infected subjects treated memory t-cell functions full article pdf cancer immunotherapy early immune responses privacy choices/manage cookies vaccine formulation including severe immune impairment individual immune responsiveness check access instant access immune adjuvant effect circulating dendritic cells formulating future vaccines technical support provided candidate idiotype vaccine article circelli pattern recognition receptors central memory innate immune detection anti-tumor efficacy antigen presenting cells cancer patients cancer vaccines institutional “ricerca corrente rnadjuvant® developed adoptive cell transfer analyze network dynamics microbial nucleic acids da tavares sf

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Immunological effects of a novel RNA-based adjuvant in liver cancer patients
         description:Evaluation of biological effects of adjuvants on immune cells has been assessed in a limited number of studies. Moreover, no data are available on samples derived from cancer patients who may have a severe immune impairment. The effects of a novel RNA-based adjuvant (RNAdjuvant® developed by CureVac) were assessed in an ex vivo setting on PBMCs obtained from 8 healthy volunteers and 17 HCC patients, using a multiparametric approach to analyze network dynamics of early immune responses. Evaluation of CD80, CD86 and HLA-DR expression, cytokine production as well as gene expression was performed. Moreover, the downstream effect on CD4+ T cell phenotyping was evaluated. Treatment with RNAdjuvant® showed comparable effects on PBMCs of both HCC and healthy subjects. In particular, CD80, CD86 and HLA-DR expression was found up-regulated in circulating dendritic cells, which promoted a CD4+ T cell differentiation toward an effector phenotype. A mixed Th1/Th2 cytokine pattern was induced, although a more predominant production of TNFα and IFNγ was observed in HCC patients versus healthy controls. The cytokine profile was further confirmed by gene transcriptional analysis, which showed up-regulation of several genes involved in innate and adaptive immune-related pathways. The present study is the first demonstration that HCC patients and healthy subjects are equally responsive to an adjuvant. This may suggest that the same vaccine formulation including the RNAdjuvant® might have similar potency in healthy subjects and cancer patients.
         datePublished:2016-11-10T00:00:00Z
         dateModified:2016-11-10T00:00:00Z
         pageStart:103
         pageEnd:112
         sameAs:https://doi.org/10.1007/s00262-016-1923-5
         keywords:
            RNAdjuvant
            Hepatocellular carcinoma
            Immune response
            Cancer vaccine
            Oncology
            Immunology
            Cancer Research
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-016-1923-5/MediaObjects/262_2016_1923_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-016-1923-5/MediaObjects/262_2016_1923_Fig2_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-016-1923-5/MediaObjects/262_2016_1923_Fig3_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-016-1923-5/MediaObjects/262_2016_1923_Fig4_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-016-1923-5/MediaObjects/262_2016_1923_Fig5_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-016-1923-5/MediaObjects/262_2016_1923_Fig6_HTML.gif
         isPartOf:
            name:Cancer Immunology, Immunotherapy
            issn:
               1432-0851
               0340-7004
            volumeNumber:66
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer Berlin Heidelberg
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Luisa Circelli
               affiliation:
                     name:Istituto Nazionale per lo Studio e la Cura dei Tumori, “Fondazione Pascale” – Istituto di Ricovero e Cura a Caratteres Scientifico (IRCCS)
                     address:
                        name:Exper. Immunotherapy Lab., Molecular Biology and Viral Oncogenesis Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, “Fondazione Pascale” – Istituto di Ricovero e Cura a Caratteres Scientifico (IRCCS), Naples, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Annacarmen Petrizzo
               affiliation:
                     name:Istituto Nazionale per lo Studio e la Cura dei Tumori, “Fondazione Pascale” – Istituto di Ricovero e Cura a Caratteres Scientifico (IRCCS)
                     address:
                        name:Exper. Immunotherapy Lab., Molecular Biology and Viral Oncogenesis Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, “Fondazione Pascale” – Istituto di Ricovero e Cura a Caratteres Scientifico (IRCCS), Naples, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Maria Tagliamonte
               affiliation:
                     name:Istituto Nazionale per lo Studio e la Cura dei Tumori, “Fondazione Pascale” – Istituto di Ricovero e Cura a Caratteres Scientifico (IRCCS)
                     address:
                        name:Exper. Immunotherapy Lab., Molecular Biology and Viral Oncogenesis Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, “Fondazione Pascale” – Istituto di Ricovero e Cura a Caratteres Scientifico (IRCCS), Naples, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Regina Heidenreich
               affiliation:
                     name:CureVac AG
                     address:
                        name:CureVac AG, Tübingen, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Maria Lina Tornesello
               affiliation:
                     name:Istituto Nazionale per lo Studio e la Cura dei Tumori, “Fondazione Pascale” – Istituto di Ricovero e Cura a Caratteres Scientifico (IRCCS)
                     address:
                        name:Exper. Immunotherapy Lab., Molecular Biology and Viral Oncogenesis Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, “Fondazione Pascale” – Istituto di Ricovero e Cura a Caratteres Scientifico (IRCCS), Naples, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Franco M. Buonaguro
               affiliation:
                     name:Istituto Nazionale per lo Studio e la Cura dei Tumori, “Fondazione Pascale” – Istituto di Ricovero e Cura a Caratteres Scientifico (IRCCS)
                     address:
                        name:Exper. Immunotherapy Lab., Molecular Biology and Viral Oncogenesis Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, “Fondazione Pascale” – Istituto di Ricovero e Cura a Caratteres Scientifico (IRCCS), Naples, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Luigi Buonaguro
               url:http://orcid.org/0000-0002-6380-7114
               affiliation:
                     name:Istituto Nazionale per lo Studio e la Cura dei Tumori, “Fondazione Pascale” – Istituto di Ricovero e Cura a Caratteres Scientifico (IRCCS)
                     address:
                        name:Exper. Immunotherapy Lab., Molecular Biology and Viral Oncogenesis Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, “Fondazione Pascale” – Istituto di Ricovero e Cura a Caratteres Scientifico (IRCCS), Naples, Italy
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Immunological effects of a novel RNA-based adjuvant in liver cancer patients
      description:Evaluation of biological effects of adjuvants on immune cells has been assessed in a limited number of studies. Moreover, no data are available on samples derived from cancer patients who may have a severe immune impairment. The effects of a novel RNA-based adjuvant (RNAdjuvant® developed by CureVac) were assessed in an ex vivo setting on PBMCs obtained from 8 healthy volunteers and 17 HCC patients, using a multiparametric approach to analyze network dynamics of early immune responses. Evaluation of CD80, CD86 and HLA-DR expression, cytokine production as well as gene expression was performed. Moreover, the downstream effect on CD4+ T cell phenotyping was evaluated. Treatment with RNAdjuvant® showed comparable effects on PBMCs of both HCC and healthy subjects. In particular, CD80, CD86 and HLA-DR expression was found up-regulated in circulating dendritic cells, which promoted a CD4+ T cell differentiation toward an effector phenotype. A mixed Th1/Th2 cytokine pattern was induced, although a more predominant production of TNFα and IFNγ was observed in HCC patients versus healthy controls. The cytokine profile was further confirmed by gene transcriptional analysis, which showed up-regulation of several genes involved in innate and adaptive immune-related pathways. The present study is the first demonstration that HCC patients and healthy subjects are equally responsive to an adjuvant. This may suggest that the same vaccine formulation including the RNAdjuvant® might have similar potency in healthy subjects and cancer patients.
      datePublished:2016-11-10T00:00:00Z
      dateModified:2016-11-10T00:00:00Z
      pageStart:103
      pageEnd:112
      sameAs:https://doi.org/10.1007/s00262-016-1923-5
      keywords:
         RNAdjuvant
         Hepatocellular carcinoma
         Immune response
         Cancer vaccine
         Oncology
         Immunology
         Cancer Research
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-016-1923-5/MediaObjects/262_2016_1923_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-016-1923-5/MediaObjects/262_2016_1923_Fig2_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-016-1923-5/MediaObjects/262_2016_1923_Fig3_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-016-1923-5/MediaObjects/262_2016_1923_Fig4_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-016-1923-5/MediaObjects/262_2016_1923_Fig5_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-016-1923-5/MediaObjects/262_2016_1923_Fig6_HTML.gif
      isPartOf:
         name:Cancer Immunology, Immunotherapy
         issn:
            1432-0851
            0340-7004
         volumeNumber:66
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer Berlin Heidelberg
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Luisa Circelli
            affiliation:
                  name:Istituto Nazionale per lo Studio e la Cura dei Tumori, “Fondazione Pascale” – Istituto di Ricovero e Cura a Caratteres Scientifico (IRCCS)
                  address:
                     name:Exper. Immunotherapy Lab., Molecular Biology and Viral Oncogenesis Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, “Fondazione Pascale” – Istituto di Ricovero e Cura a Caratteres Scientifico (IRCCS), Naples, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Annacarmen Petrizzo
            affiliation:
                  name:Istituto Nazionale per lo Studio e la Cura dei Tumori, “Fondazione Pascale” – Istituto di Ricovero e Cura a Caratteres Scientifico (IRCCS)
                  address:
                     name:Exper. Immunotherapy Lab., Molecular Biology and Viral Oncogenesis Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, “Fondazione Pascale” – Istituto di Ricovero e Cura a Caratteres Scientifico (IRCCS), Naples, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Maria Tagliamonte
            affiliation:
                  name:Istituto Nazionale per lo Studio e la Cura dei Tumori, “Fondazione Pascale” – Istituto di Ricovero e Cura a Caratteres Scientifico (IRCCS)
                  address:
                     name:Exper. Immunotherapy Lab., Molecular Biology and Viral Oncogenesis Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, “Fondazione Pascale” – Istituto di Ricovero e Cura a Caratteres Scientifico (IRCCS), Naples, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Regina Heidenreich
            affiliation:
                  name:CureVac AG
                  address:
                     name:CureVac AG, Tübingen, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Maria Lina Tornesello
            affiliation:
                  name:Istituto Nazionale per lo Studio e la Cura dei Tumori, “Fondazione Pascale” – Istituto di Ricovero e Cura a Caratteres Scientifico (IRCCS)
                  address:
                     name:Exper. Immunotherapy Lab., Molecular Biology and Viral Oncogenesis Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, “Fondazione Pascale” – Istituto di Ricovero e Cura a Caratteres Scientifico (IRCCS), Naples, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Franco M. Buonaguro
            affiliation:
                  name:Istituto Nazionale per lo Studio e la Cura dei Tumori, “Fondazione Pascale” – Istituto di Ricovero e Cura a Caratteres Scientifico (IRCCS)
                  address:
                     name:Exper. Immunotherapy Lab., Molecular Biology and Viral Oncogenesis Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, “Fondazione Pascale” – Istituto di Ricovero e Cura a Caratteres Scientifico (IRCCS), Naples, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Luigi Buonaguro
            url:http://orcid.org/0000-0002-6380-7114
            affiliation:
                  name:Istituto Nazionale per lo Studio e la Cura dei Tumori, “Fondazione Pascale” – Istituto di Ricovero e Cura a Caratteres Scientifico (IRCCS)
                  address:
                     name:Exper. Immunotherapy Lab., Molecular Biology and Viral Oncogenesis Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, “Fondazione Pascale” – Istituto di Ricovero e Cura a Caratteres Scientifico (IRCCS), Naples, Italy
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Cancer Immunology, Immunotherapy
      issn:
         1432-0851
         0340-7004
      volumeNumber:66
Organization:
      name:Springer Berlin Heidelberg
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Istituto Nazionale per lo Studio e la Cura dei Tumori, “Fondazione Pascale” – Istituto di Ricovero e Cura a Caratteres Scientifico (IRCCS)
      address:
         name:Exper. Immunotherapy Lab., Molecular Biology and Viral Oncogenesis Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, “Fondazione Pascale” – Istituto di Ricovero e Cura a Caratteres Scientifico (IRCCS), Naples, Italy
         type:PostalAddress
      name:Istituto Nazionale per lo Studio e la Cura dei Tumori, “Fondazione Pascale” – Istituto di Ricovero e Cura a Caratteres Scientifico (IRCCS)
      address:
         name:Exper. Immunotherapy Lab., Molecular Biology and Viral Oncogenesis Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, “Fondazione Pascale” – Istituto di Ricovero e Cura a Caratteres Scientifico (IRCCS), Naples, Italy
         type:PostalAddress
      name:Istituto Nazionale per lo Studio e la Cura dei Tumori, “Fondazione Pascale” – Istituto di Ricovero e Cura a Caratteres Scientifico (IRCCS)
      address:
         name:Exper. Immunotherapy Lab., Molecular Biology and Viral Oncogenesis Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, “Fondazione Pascale” – Istituto di Ricovero e Cura a Caratteres Scientifico (IRCCS), Naples, Italy
         type:PostalAddress
      name:CureVac AG
      address:
         name:CureVac AG, Tübingen, Germany
         type:PostalAddress
      name:Istituto Nazionale per lo Studio e la Cura dei Tumori, “Fondazione Pascale” – Istituto di Ricovero e Cura a Caratteres Scientifico (IRCCS)
      address:
         name:Exper. Immunotherapy Lab., Molecular Biology and Viral Oncogenesis Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, “Fondazione Pascale” – Istituto di Ricovero e Cura a Caratteres Scientifico (IRCCS), Naples, Italy
         type:PostalAddress
      name:Istituto Nazionale per lo Studio e la Cura dei Tumori, “Fondazione Pascale” – Istituto di Ricovero e Cura a Caratteres Scientifico (IRCCS)
      address:
         name:Exper. Immunotherapy Lab., Molecular Biology and Viral Oncogenesis Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, “Fondazione Pascale” – Istituto di Ricovero e Cura a Caratteres Scientifico (IRCCS), Naples, Italy
         type:PostalAddress
      name:Istituto Nazionale per lo Studio e la Cura dei Tumori, “Fondazione Pascale” – Istituto di Ricovero e Cura a Caratteres Scientifico (IRCCS)
      address:
         name:Exper. Immunotherapy Lab., Molecular Biology and Viral Oncogenesis Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, “Fondazione Pascale” – Istituto di Ricovero e Cura a Caratteres Scientifico (IRCCS), Naples, Italy
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Luisa Circelli
      affiliation:
            name:Istituto Nazionale per lo Studio e la Cura dei Tumori, “Fondazione Pascale” – Istituto di Ricovero e Cura a Caratteres Scientifico (IRCCS)
            address:
               name:Exper. Immunotherapy Lab., Molecular Biology and Viral Oncogenesis Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, “Fondazione Pascale” – Istituto di Ricovero e Cura a Caratteres Scientifico (IRCCS), Naples, Italy
               type:PostalAddress
            type:Organization
      name:Annacarmen Petrizzo
      affiliation:
            name:Istituto Nazionale per lo Studio e la Cura dei Tumori, “Fondazione Pascale” – Istituto di Ricovero e Cura a Caratteres Scientifico (IRCCS)
            address:
               name:Exper. Immunotherapy Lab., Molecular Biology and Viral Oncogenesis Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, “Fondazione Pascale” – Istituto di Ricovero e Cura a Caratteres Scientifico (IRCCS), Naples, Italy
               type:PostalAddress
            type:Organization
      name:Maria Tagliamonte
      affiliation:
            name:Istituto Nazionale per lo Studio e la Cura dei Tumori, “Fondazione Pascale” – Istituto di Ricovero e Cura a Caratteres Scientifico (IRCCS)
            address:
               name:Exper. Immunotherapy Lab., Molecular Biology and Viral Oncogenesis Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, “Fondazione Pascale” – Istituto di Ricovero e Cura a Caratteres Scientifico (IRCCS), Naples, Italy
               type:PostalAddress
            type:Organization
      name:Regina Heidenreich
      affiliation:
            name:CureVac AG
            address:
               name:CureVac AG, Tübingen, Germany
               type:PostalAddress
            type:Organization
      name:Maria Lina Tornesello
      affiliation:
            name:Istituto Nazionale per lo Studio e la Cura dei Tumori, “Fondazione Pascale” – Istituto di Ricovero e Cura a Caratteres Scientifico (IRCCS)
            address:
               name:Exper. Immunotherapy Lab., Molecular Biology and Viral Oncogenesis Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, “Fondazione Pascale” – Istituto di Ricovero e Cura a Caratteres Scientifico (IRCCS), Naples, Italy
               type:PostalAddress
            type:Organization
      name:Franco M. Buonaguro
      affiliation:
            name:Istituto Nazionale per lo Studio e la Cura dei Tumori, “Fondazione Pascale” – Istituto di Ricovero e Cura a Caratteres Scientifico (IRCCS)
            address:
               name:Exper. Immunotherapy Lab., Molecular Biology and Viral Oncogenesis Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, “Fondazione Pascale” – Istituto di Ricovero e Cura a Caratteres Scientifico (IRCCS), Naples, Italy
               type:PostalAddress
            type:Organization
      name:Luigi Buonaguro
      url:http://orcid.org/0000-0002-6380-7114
      affiliation:
            name:Istituto Nazionale per lo Studio e la Cura dei Tumori, “Fondazione Pascale” – Istituto di Ricovero e Cura a Caratteres Scientifico (IRCCS)
            address:
               name:Exper. Immunotherapy Lab., Molecular Biology and Viral Oncogenesis Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, “Fondazione Pascale” – Istituto di Ricovero e Cura a Caratteres Scientifico (IRCCS), Naples, Italy
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Exper. Immunotherapy Lab., Molecular Biology and Viral Oncogenesis Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, “Fondazione Pascale” – Istituto di Ricovero e Cura a Caratteres Scientifico (IRCCS), Naples, Italy
      name:Exper. Immunotherapy Lab., Molecular Biology and Viral Oncogenesis Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, “Fondazione Pascale” – Istituto di Ricovero e Cura a Caratteres Scientifico (IRCCS), Naples, Italy
      name:Exper. Immunotherapy Lab., Molecular Biology and Viral Oncogenesis Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, “Fondazione Pascale” – Istituto di Ricovero e Cura a Caratteres Scientifico (IRCCS), Naples, Italy
      name:CureVac AG, Tübingen, Germany
      name:Exper. Immunotherapy Lab., Molecular Biology and Viral Oncogenesis Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, “Fondazione Pascale” – Istituto di Ricovero e Cura a Caratteres Scientifico (IRCCS), Naples, Italy
      name:Exper. Immunotherapy Lab., Molecular Biology and Viral Oncogenesis Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, “Fondazione Pascale” – Istituto di Ricovero e Cura a Caratteres Scientifico (IRCCS), Naples, Italy
      name:Exper. Immunotherapy Lab., Molecular Biology and Viral Oncogenesis Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, “Fondazione Pascale” – Istituto di Ricovero e Cura a Caratteres Scientifico (IRCCS), Naples, Italy
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(127)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Particles.js
Prism.js

4.32s.

LINK . SPRINGER . COM {}